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Rapport de synthèse 
Utilisation d'un substitut nicotinique prescrit une fois par heure versus ad libitum chez 
des fumeurs présentant une dépendance nicotinique forte et voulant arrêter de fumer : 
une étude randomisée contrôlée 
1. Objectif 
Evaluer l'effet qu'ont les consignes d'utilisation régulière d'un spray nasal à la nicotine sur 
leur véritable utilisation durant les 3 premières semaines d'un sevrage tabagique. Un objectif 
secondaire est d'évaluer l'effet des consignes d'utilisation régulière du spray durant les 
premières semaines de sevrage tabagique sur le taux de succès à 6 mois par rapport à un 
groupe pouvant utiliser le spray « ad libitum ». 
2. Méthode 
Il s'agit d'une étude ouverte, randomisée contrôlée, incluant 50 patients présentant une 
dépendance nicotinique forte, se trouvant en phase de préparation selon le modèle trans-
théorique du changement de Prochaska et Di Clemente, recrutés au sein de la consultation 
«stop tabac» de la Policlinique Médicale Universitaire de Lausanne. Dans le groupe 
« contrôle », les patients ont été instruits à utiliser le spray « ad libitum», soit dès 
qu'apparaissaient des envies irrésistibles de fumer, tandis que le groupe « intervention » a 
reçu pour consigne d'utiliser le spray au moins 1 fois par heure dès le lever, voire plus en cas 
d'envie de fumer. L'utilisation du spray nasal a été enregistrée par un dispositif électronique 
fixé sur le spray (MDILog™) durant les 3 premières semaines d'utilisation. Durant le suivi, 
l'abstinence tabagique a été vérifiée par une mesure du taux de CO expiré par un appareil 
spécifique (Bedfont Smokerlyzer). L'abstinence tabagique a été considérée comme un succès 
si le taux de CO était:::; 10 ppm (particules par million). 
3. Résultats 
Un patient a été perdu durant le suivi. Au moment de la randomisation, le groupe 
«intervention» comprenait plus de femmes, des patients ayant un nombre plus grand de 
précédentes tentatives d'arrêt du tabagisme, plus de co-morbidités psychiatriques, mais moins 
de co-morbidités somatiques que le groupe «contrôle». Dans les 2 groupes, les participants 
ont utilisé le spray nasal plus de 8 fois par jour (minimum demandé dans le groupe 
intervention). L'utilisation moyenne du spray était de 13 ,6 doses/jour pour le groupe 
« intervention » et de 11,1 doses/jour pour le groupe contrôle. Ajusté aux différences entre les 
2 groupes, la différence entre les doses plus importantes utilisées dans le groupe 
« intervention» par rapport à celles du groupe « ad libitum» reste non significative durant la 
première (0.8 ; CI 95% -5.l ; 6,7), la deuxième (4.0; CI 95% -1.9; 9.9) et la troisième 
semaine (3.0; CI 95% -2.5; 8.5). De même, le fait d'instruire le patient à utiliser chaque 
heure le spray nasal durant les premières semaines n'a pas eu d'impact sur le taux de succès à 
6 mois (RR = 0.69; CI 95% 0.34; 1.39). 
4. Conclusions 
Cette étude négative montre que les différences d'utilisation du spray nasal nicotinique sont 
plus dépendantes des caractéristiques individuelles du patient que des recommandations 
d'utilisation du thérapeute. Les patients présentant un syndrome de dépendance à la nicotine 
forte utilisent spontanément de manière importante le spray nasal nicotinique, 
indépendamment des recommandations données. Pour les patients présentant un syndrome de 
dépendance à la nicotine forte, les recommandations par le thérapeute d'utiliser le spray nasal 
dès l'apparition d'envies de fumer semblent être la manière de faire la plus adéquate. 
() Substance Abuse Treatment, 
Prevention,. and Policy BioMed Central 
Research 
Use of nicotine substitute prescribed at hourly plus ad libitum 
intake or ad libitum for heavy smokers willing to quit: a randomized 
controlled trial 
Laurent Reyt, Paul Vauchert, Françoise Secretan, Jean-Pierre Zellweger and 
Patrick Bodenmann * 
Address: Department of Ambulatory Care and Community Medicine, University of Lausanne, Switzerland 
Email: Laurent Rey - Laurent.Rey@hin.ch; Paul Vaucher - paul.vaucher@hospvd.ch; Françoise Secretan - francoise.secretan@hospvd.ch; Jean-
Pierre Zellweger - zellwegerjp@swissonline.ch; Patrick Bodenmann * - patrick.bodenmann@hospvd.ch 
* Corresponding author tEqual contributors 
Published: 2 June 2009 
Substance Abuse Treatment, Prevention, and Policy 2009, 4: 12 doi: 10.1 186/ l 747-597X-4- l 2 
This article is available from: http://www.substanceabusepolicy.com/content/4/ 1/12 
© 2009 Rey et al; licensee BioMed Central Ltd. 
Received: 19 March 2009 
Accepted: 2 June 2009 
This is an Open Access article distributed un der the terms of the Creative Commons Attribution License (http://creatiyecommons,org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Abstract 
Objective: T o assess the impact of instructional guidance in the regular use of use nicotine nasal spray 
(NNS) on the true use of NNS during the first three weeks of smoking cessation for heavy smokers who 
are willing to quit. 
Methods: This randomized, open, controlled trial included 50 patients who were heavy smokers, were 
willing to quit, and attending an academic outpatient clinic in Western Switzerland. Patients were 
randomised to instruction on NNS use as "ad libitum" (administration whenever cravings appear; control 
group) or to use NNS when craving appears and at least every hour when awake (intervention group). 
lntakes were monitored using an electronic device fixed in the spray unit (MDILog ™) during the first three 
weeks of use. Self reported abstinence from smoking at six months was confirmed by expired-air carbon 
monoxide. Using intention-to-treat analysis, random-effect GLS regression was used to calculate the mean 
difference of daily doses between groups controlling for lack of independence between measures from the 
same individual. 
Results: One patient was lost to follow-up. At baseline randomization, the group receiving instruction to 
use NNS hourly included more women, patients with previous desires to quit, and patients with more 
psychiatrie comorbidities and less somatic complaints compared to the group instructed to use NNS with 
cravings (group imbalance). Both groups self-administered more than the daily recommended dosage of 8 
uses. Mean daily usage was 13.6 dose/day and 11.1 dose/day for the group instructed to use NNS hourly 
and with cravings, respectively. Adjusting for baseline imbalance, the increased daily doses in the 
intervention group (hourly use) remained nonsignificant compared to ad libitum use (-0.5 dose/day; Cl 95% 
-6.2; 5.3, from day 1 to day 7; and 2.3 dose/day; Cl 95% -5.4; 10.0, from day 8 to day 21 ). lnstructing patients 
to use the NNS daily had no effect on smoking cessation at six months (RR = 0.69; Cl 95% 0.34; 1.39). 
Conclusion: Heavy smokers willing to quit use NNS frequently, regardless of the instructions given. 
Recommending the use of NNS only when craving appears for heavy smokers willing to quit seems 
acceptable compared to prescribing hourly administration. 
Trial registration-: ClinicalTrials.gov: NCT0086 l 276 
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Background 
Cigarette smoking is currently the greatest preventable 
cause of death in our society; smoking cessation is 
regarded as one of the important preventive practices in 
modern medicine [1]. Use of nicotine replacement prod-
ucts increases the rate of smoking cessation 1.5 to 2 fold 
[2]. Nevertheless, there is uncertainty about the relation-
ship between dose of replacement products, pattern of 
use, and success rate. Regarding the use of nicotine gum, 
improved outcome is reported with fixed dose rather than 
ad libitum usage [3]. Increasing the dose of nicotine 
replacement therapy has been shown to increase success 
rate [4 ]. Nicotine nasal spray (NNS) was developed to 
allow rapid delivery of nicotine through the nasal 
mucosa, allowing more rapid absorption than with the 
nicotine patch or gum. This rapid absorption and the 
user's ability to control the rate of use with NNS allow 
subjects to adjust the dose as needed. This type of nicotine 
substitution is particularly suitable for highly dependent 
smokers [5], willing to quit but with acute episodes of 
craving [ 6]. Different patterns of use have been observed 
between successful quitters and failures; successful quit-
ters reportedly use higher doses [7]. Prescribing regularly 
scheduled use of NNS rather than instructing the patient 
to use the spray only when desired may improve the 
number of successful quitters. However, little is known 
regarding the response of patients to instructions for reg-
ular, scheduled use of nicotine substitutes. The aim of our 
study is to assess the effect of instructions for regular use 
of NNS on the true use of NNS during the first three weeks 
of attempted quitting; a secondary aim is to assess the 
effect of instruction for regular NNS use on smoking ces-
sation success rates at 6 months compared with the cur-
rently recommended "ad libitum" use. 
Methods 
Participants 
This open, randomized, controlled study was conducted 
in a group of 50 highly dependent smokers seen in the 
Department of Ambulatory care and Community Medi-
cine in Lausanne, Switzerland. Patients were defined as 
highly dependent using Fagerstrom's criteria modified by 
Heatherton and al (smoking;::.: 20 cigarettes/day and/or 
smoking the first cigarette within 30 minutes after wak-
ing) [8]. To be included, patients had to be in the stage of 
preparation according to Prochaska and Di Clemente's 
stages of change model [9]. Exclusion criteria were a his-
tory of myocardial infarction in the preceding 3 months, 
pregnancy or breast-feeding, and use of any form of 
smokeless tobacco or other nicotine replacement therapy. 
At inclusion, demographic characteristics, smoking his-
tory, and nicotine dependence were recorded, and partic-
ipants were asked about their smoking habits, prior quit 
attempts, current or prior psychiatrie treatment, and moti-
vation to quit. Subjects gave written informed consent to 
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participate in the trial. The participants received advice to 
stop smoking completely at a fixed quit date. They were 
instructed how to use the NNS to enhance its acceptability 
and reduce local adverse effects. 
Randomization, allocation, blinding 
Prior to data collection, a pharmacist prepared a randomi-
zation list of 50 blinded shuffled paper slips including 25 
As and 25 Bs which were used to assign patients to treat-
ment groups. Each paper slip was sealed in an opaque 
numbered envelope. Once a patient was included in the 
study and baseline data was collected, the sealed envelope 
was opened by the investigator to reveal the patient's allo-
cation. Patients were blinded to the other intervention but 
were aware of their own. Investigator could not be 
blinded, as he was to give instructions on the use of NNS. 
During follow-up, the research nurse was not expressively 
made aware of the allocation but made all patients aware 
of the importance of using the spray when craving 
appeared. Statistician was blinded to which group 
received which intervention until the end of the analysis. 
Intervention 
During the first month, subjects in the intervention group 
received instruction from the physician to use NNS when 
craving appears and at least 2 puffs/hour, for an average of 
1 mg nicotine/hour when awake. Instructions were given 
to the patient as if this was the usual way of using the 
NNS. 
Contrai 
In the control group, participants were instructed to use 
NNS as needed to suppress withdrawal symptoms when 
cravings appeared. 
In both groups, 1) the use of NNS was free during the first 
two months, 2) during follow-up, physicians were trained 
to advise patients who experience craving to use the spray 
more often, 3) after one month, participants were advised 
to reduce the use of NNS if tolerable. 
Outcomes 
During the first mon th, the number of puffs was recorded 
with an electronic device fixed on the spray unit (micros-
witch-actuated metered-dose inhaler chronology, 
MDILog"', model MDC-511, Medtrac, Denver, Colorado 
USA). The MDILog"' recorded the date and time of each 
activation. Only full days were taken into consideration; 
this means that the first day of use was not monitored. 
Doses are defined as grouped puffs that are spaced less 
than one minute apart. A series was defined as a sequence 
of puffs separated by more than one second but less than 
one minute. The normal number of puffs per dose should 
be two. Puffs that were monitored at the same second 
were counted as single. 
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Participants were informed of the aim of the MDILog"', 
but they did not see the results. Because the MDILog"' sys-
tem showed variable reliability in previous studies [7], we 
followed a precise validation protocol to ensure data qual-
ity. Participants were asked to return their MDILog"' and 
all bottles of nicotine ( empty, started, or full) at each visit. 
The research nurse checked every MDILog™ thoroughly 
with a software program and compared the total record of 
puffs since the last visit with the weight of the returned 
nasal spray bottles. If any technical deficiency or record 
discrepancy was detected, the MDILog"' was changed. 
Patients were monitored during the first mon th of use (a 
total of 27 to 35 days). Five patients had missing data 
completely at random due to the MDILog""s initial tech-
nical failures. The trial steering committee therefore 
decided to extract data from the 21st full days of use 
instead of the initial 28 that were planned. All patients 
were instructed to administer two puffs for every dose. 
Data was collected to evaluate the number of series that 
had more or less than two puffs. 
The criterion of abstinence was self-reported continuous 
abstinence from smoking from the beginning of the sub-
stitution to the end of the 6th month of follow-up, vali-
dated by an expired-air carbon monoxide (CO) 
concentration of less than 10 parts per million (ppm) at 
all visits (Bedfont Smokerlyzer, Bedfont Scientific Ltd., 
Rochester, UK). "Occasional slips" (i.e. less than 1 ciga-
rette/day during the examined period) were tolerated. 
Smoking cessation was defined as successful in patients 
with smoking abstinence or "occasional slips" with a CO 
rate :::; 10 ppm. 
Follow-up visits were scheduled at 1 and 2 weeks and at 1, 
2, 3, and 6 months. At each follow-up visit, participants 
were asked about cigarette consumption during the last 24 
hours, smoking since last visit, and average number of 
puffs of NNS daily. 
Statistical analysis 
The number of daily intakes was measured for each sub-
ject from bath groups during the initial 21 days of moni-
toring (D+ 1 to D+ 22). Differences of daily intake between 
groups were computed using random-effect generalised 
least square regression ( GLS) to take into account the lack 
of independence between measurements from the same 
participants. Interclass correlation coefficients were 
reported to estimate the proportion of variance related to 
individual characteristics. The analysis was stratified by 
week to see if differences between groups were constant 
through time and by weekdays. If important group imbal-
ance was observed (>20% relative difference between 
groups), these factors were to be included secondarily in 
the regression analysis for adjustment. 
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Proportion of success were calculated for each group at 1 
week, 2 weeks, 1 month, 2 months, 3 months, and 6 
months with a 95% confidence interval (CI 95%). Rela-
tive risk (RR) of success at six months between groups was 
computed with CI 95%. P value was given for chances of 
a RR of 1 (chances that the intervention has the same 
effect as the control on smoking cessation). 
Sample size was calculated for the primary objective only. 
Using data from a previous study [7], the expected average 
number of daily puffs (2 puffs = 1 dose) is expected to be 
9 with a standard deviation (SD) of8. The sample size was 
calculated to detect an increase up to 16 daily puffs (8 
doses) with a significance level set at 0.05 and a power of 
0.8. Each group was to include 21 participants. Expecting 
dropouts, the number of patients to be included was 
rounded to 25 per group. All calculations were performed 
with StataCorp. 2008 Statistical Software, Release 10.0 
(College Station, Texas: Stata Corporation). 
The study was approved by the ethical review committee 
for clinical research of the Department of Internal Medi-
cine, University of Lausanne (Prat 29/99). 
Results 
Data was collected from June 2000 to December 2001. As 
planned, 25 patients were included in each group. Four 
patients ( two from each group) did not use their NNS 
from the second day on; two because of the side effects 
occurring at the testing session and two because they did 
not feel ready to quit smoking. These patients were 
included in the intention to treat analysis. One participant 
from the intervention group moved away and was lost to 
follow-up after his encounter at three months (Figure 1 ). 
Balance between groups was not achieved (Table 1 ). The 
intervention group included more females ( 40% vs. 
16% ), participants who had fewer previous attempts to 
quit smoking (2.2 vs. 3 .1 ), had more co-occurring psychi-
atrie disorders ( 44% vs. 24% ), and fewer somatic com-
plaints (56% vs. 70.1 % ) than the control group (Table 1 ). 
NNS were used similarly between patients from bath 
groups with important variances; these differences were 
due to individual characteristics rather than the interven-
tion (Table 2). The calculated total number of 0.5 mg 
puffs highly correlated with the weighed consumption of 
NNS (r = 0.947; p < 0.001). After their physician visit, 
patients who were counselled to use the NNS hourly used 
the NNS an average of 13.6 times a day whereas those 
instructed to use it when cravings appeared used the NNS 
an average of 11.1 times per day; Figure 2 shows mean 
daily use of NNS. Patients told to use the NNS once every 
hour, 12 times a day, used an average 2.6 (CI95% -2.7; 
7.9) more doses every day compared to those told to use 
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Flow Chart. 
.. 
the NNS when craving appeared; this difference was non 
significant. The fraction of variance due to individual 
characteristics other than of the prescribed intervention 
(instructed use of NNS) was 0.606. The difference in the 
number of daily doses between groups was less important 
during the first week (0.8; CI 95% -5.1; 6.7) than during 
the second ( 4.0; CI 95% -1.9; 9.9) and third week (3.0; CI 
95% -2.5; 8.5). Including the patient's daily number of 
smoked cigarettes in the regression model did not 
improve the likelihood ratio of the model to predict the 
daily dose intake of NNS; the observed variance between 
patients cannot be explained by the patient's frequency of 
smoking before cessation. 
N=24 
Â 
Adjusting for group imbalance (sex, psychiatrie comor-
bidities, number of previous desires to quit) and stratify-
ing the analysis between day 1 to 7 and day 8 to 21, the 
observed increase in the number of daily doses was -0.5 
(CI95% -6.2; 5.3) from day 1 to 7 and 2.3 (CI95% -5.4; 
10.0) from day 8 to day 21. 
The proportion of abstinent patients over time is shown 
in Figure 3. A total of 8 of 24 patients in the intervention 
arm and 12 of 25 patients in the control group success-
fully stopped smoking at 6 month follow up. Patients 
receiving instruction to use NNS once per hour had a 
lower cessation rate compared to those instructed to use 
the NNS when cravings appeared (relative risk of 0.69, 
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Table 1: Patients' baseline characteristics. 
NNS NNS 
1 dose per hour/12 h a day 
n = 25 
Dose when cravings appear (contrai) 
n = 25 
Age 
Mean (SD) 
Sex 
% male* 
Education 
% high school/university 
Health 
Psychiatrie comorbidities* 
Smoking habits 
Daily intake; mean cig/day (SD) 
Baseline CO (ppm); mean (SD) 
Years of consumption; mean (SD) 
Previous attempts; mean (SD)* 
40.2 (11.4) 
60% 
52% 
44% 
29.8 (11.4) 
42.0 (16.1) 
18.9 (11.0) 
2.2 (1.7) 
*Over 20% relative difference between groups. 
Cig: cigarettes; CO: carbon monoxide; SD: standard deviation. 
CI95% 0.34; 1.39) although the difference was not signif-
icant (Fisher's exact test, p = 0.296). Eleven patients who 
had not ceased smoking reported a reduction in cigarette 
consumption (five in the intervention group and six from 
the control group). However, at six months only one 
patient smoked less than 50% of the initial amount while 
continuing to use the NNS. 
Discussion 
This negative study shows that differences in NNS intake 
are more dependent on individual characteristics than on 
the recommended frequency of use. We observed frequent 
use of nasal spray in bath groups. Average use was 13.6 
intakes/ day and 11.1 intakes/ day in groups instructed to 
use NNS hourly versus with cravings, respectively. Nico-
Cl 
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Mean number of intal<es tal<en daily for patients told 
to use NNS at least once every hour and for those 
told to use NSS every time cravings appear. 
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84% 
58.3% 
24% 
30 (10.3) 
40.9 (19.0) 
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3.1 (3.1) 
tine doses were higher in bath groups than those recom-
mended by the manufacturer ( 8 daily intakes) and 
observed by Mabry et al [10]. Physicians were trained to 
follow patients and encourage them to use the NNS as 
muchas possible to prevent craving and relapse. Further-
more, patients were all heavy smokers willing to quit, 
which could explain their regular use of the NNS inde-
pendently of the given recommendation. Even if a slight 
trend towards more regular use in patients instructed to 
use the NNS hourly was observed, the minimal inferred 
average intake for the control group is clinically sufficient 
to justify the actual recommendation to use the substitute 
when craving appears. Seeing the patients regularly during 
the first two months could help increase compliance with 
the recommended use of NNS. We observed in bath 
groups an increased use after visits with physicians. Feel-
ings of empathy, encouragement in their initiative, and 
receiving counselling could help improve the regular use 
of NNS. Finally, differences exist in the use of NNS 
between individual patients. These differences were how-
ever not explained by the type of instructions given nor by 
previous smoking habits. 
The proportion of success at 6 months ( 41 % ) in our study 
was slightly superior to rates seen in other studies using 
NNS, with reports varying between 10 and 35% at 6 
months [5-7,11-14]. In our study, patients were followed 
regularly and counselling was offered to support their 
effort. Counselling and support might have increased use 
of the NNS, which in turn could have helped them in 
remaining abstinent [15]. Furthermore, positive instruc-
tions on the regular use of NNS given by physicians could 
have also helped in bath groups by increasing expecta-
tions, which are known to have an important placebo 
effect [16]. A small risk of addiction to the NNS, due to the 
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Tle 2: NNS use during the first 21 full days of treatment; data from 1050 days of observation from 50 patients.* 
NNS NNS Wald Chi2 test ICCI: 
1 dose per hour Ad libitum 
Mean (Cl 95%) Mean (Cl 95%) p-value p 
Doses 
Daily number of intakes 13.6 (4.7; 22.6) 11. I (7.3; 14.8) p = 0.332 p = 0.606 
Daily number of correct doses (2 puffs) 12.0 (3.9; 20.2) 9.3 (5.9; 12.7) p = 0.263 p = 0.593 
Daily number of single puff 0.5 (-0.4; 1.5) 0.8 (0.4; 1.2) p = 0.470 p = 0.414 
Daily number of doses over 2 puffs 1.1 (-0.1; 2.2) 1.0 (0.5; 1.4) p = 0.780 p = 0.331 
Period of use 
Daily intake 1 st week 13.7 (3.6; 23.8) 12.9 (8.7; 17.1) p = 0.788 p = 0.798 
Daily intake 2°d week 14.5 (4.4;24.6) 10.5 (6.3; 14.7) p = 0.184 p = 0.696 
Daily intake 3rd week 12.8 (5.6; 22.2) 9.8 (5.8; 13.7) p = 0.287 p = 0.656 
Week days 
Daily intake weekends 13.2 (4.3; 22.2) 9.7 (6.0; 13.4) p = 0.189 p = 0.525 
Daily intake weekdays 13.8 (4.5; 23.1) 11.6 (7.7; 15.4) p = 0.419 p = 0.652 
Use of NNS 
Days NNS was usedt 22.9 (19.0; 27.3) 23.0 ( 18.8;27.3) p = 0.966 
Total nicotine (mg)t 418 (294; 543) 296 (188; 405) p = 0.131 
* Results are drawn from random-effect GLS regression taking lad< of independence from measurements from the same patients into 
consideration. 
t lndividual level data was used for this analysis. T-test was used to calculate p-value. 
t The lntraclass Correlation Coefficient (p) corresponds to the percentage of variance due to individual characteristics (cluster level). 
rapid absorption and high peak level, has been previously 
described [5,12]. However, the main reason for a pro-
longed use, as suggested by Hughes, is the fact that highly 
dependent smokers need a long transition period to 
recover from their physiological dependency [17,18]. ln 
our study, only 1 patient among 50 was still using the 
NNS at six months. He was also the only patient who was 
smoking less than 50% of the initial amount after 6 
months; all other patients who had reduced their con-
sumption relapsed. This suggests that temporary reduc-
tion is probably real (no compensatory smoking) but not 
100% 
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0 
c: 
Q) 
c: 
~ 
~ 50% 
0 
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Figure 3 
m Hourly intake prescribed +ad libitum 
D Suggested when cravlng appears 
Ici 95% 
1 week 2 weeks 1 month 2 months 3 months 6 months 
Tlme sin ce cessation 
Smoking abstinence during the 6 month follow-up 
(25 patients in each group ). One patient in the interven-
tion group was lost to follow-up after the 3 month visit. 
appropriate in the long term for highly dependent smok-
ers [19]. 
To our knowledge, this is the second study where smokers 
have been instructed to use the NNS regularly and not on 
an "ad libitum" basis. As in our study, Tonnesen et al [ 14] 
did not observe a difference in the rate of success between 
smokers instructed to use the NNS regularly or on 
demand. Mooney et al [20] did not observe any improve-
ment in the cessation rate at six months when encourag-
ing use of nicotine gum with psychological interventions 
(brief feedbacks or contingency management). Neverthe-
less, in a large randomized trial, Shiffmann et al's observa-
tions support the theory of a causal relationship between 
higher use of nicotine substitute and success [ 4]. It there-
fore seems reasonable to believe that patient's use of sub-
stitutes depend more of their own reticence [21] or 
motivations [17] rather than instructions given by their 
practitioner. 
The strength of this study is the precision in the measures 
of individual daily use of NNS using the MDILogrn and 
measuring effects of instructions in a pragmatic approach. 
The major limitation is the low power of this study. The 
small sample size resulted in clinical significant group 
imbalance for gender, co-occurring psychiatrie disorders, 
and number of previous desires to quit. Nevertheless, con-
trolling for imbalance in the regression analysis did not 
modify results. Our observations are limited to the use of 
the spray during the first month whereas most patients 
used the NNS for much longer. It cannot be excluded that 
the spray was used differently between groups after mon-
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itoring ended. This however had apparently no effect on 
the rate of success at six months. Finally, our observations 
concern heavy smokers willing to quit. Use of the NNS 
could differ for other levels of dependence or for smokers 
who are not willing to quit. 
Conclusion 
Heavy smokers willing to quit use NNS in high doses, 
whatever the instructions given. Recommending the use 
of spray when craving appears is acceptable compared to 
prescribing fixed regular doses. For heavy dependant 
smokers willing to quit, when insisting on the use of NNS 
when craving appears, it does not seem to matter what 
instructions are given on the minimal recommended daily 
administration. 
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